Discovery and Clinical Development of Dutasteride, a Potent Dual 5α-Reductase Inhibitor

    Stephen V. Frye
    Studysummary This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on eurekaselect.com →
    Discuss this study in the Community →

    Related research 1

    1. Prostate Carcinoma Der Urologe · 2011